No change in the strategic guideline for Aviva in the coming years. This is the main conclusion after the investor update published this morning by the insurer. Again, the priority will continue to be given to cost reduction (£300m on 2019-21), operating cash generation, a progressive dividend and debt reduction (£1.5bn at least by 2022). Buying Aviva remains a good choice for dividend lovers, but not necessarily a best one for investors who are looking for a growth strategy.
